InDex raises $20m to bring ulcerative colitis drug to market
This article was originally published in Scrip
Executive Summary
Swedish drug developer InDex Pharmaceuticals has raised $20m in an oversubscribed financing round, which will help the company move its lead compound Kappaproct towards the market. Kappaproct is currently in Phase III development for ulcerative colitis, with results from the COLLECT study expected in the summer.